THE RISKS, STATED PLAINLYIf this page changes your mind, it has worked. Every risk here is real, current, and stated without the qualifiers a brochure would add.

Educational overview · Approx. 5 min read · illustrative, not advice

If this page changes your mind, it has worked. Every risk here is real, current, and stated without the qualifiers a brochure would add.

Regulatory risk is live and moving toward you

Corporate practice of medicine enforcement turns on how much control a non-clinical entity exercises over clinical judgment, and 2025 moved toward tightening: Massachusetts enacted MSO ownership transparency requirements and Oregon, Washington and California saw CPOM-strengthening bills introduced.

A structure that is defensible today may face additional disclosure obligations tomorrow. If your structure only works because nobody is looking closely, plan for someone looking closely.

Marketing enforcement is equally live. FDA issued more than 50 warning letters in September 2025 to companies compounding or manufacturing semaglutide and tirzepatide over statements it deemed false or misleading. Businesses in this category get reached through their advertising more often than through their operations.

Supply risk has a docket number and a date

On April 30, 2026 FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulk drug substances list, finding no clinical need and expressly rejecting affordability and insurance access as constituting clinical need. Comments were due July 30, 2026.

This is not speculative risk. It is a proposed action with dates, and its reasoning has already dismissed the argument most commonly used to defend the compounded channel. Anyone building a model that depends on that channel should be reading the docket, not a summary of it.

The 2025 precedent is instructive: enforcement discretion ended April 22, 2025 for 503A and May 22, 2025 for 503B, and businesses whose supply and pricing depended on it had no fallback.

Pricing risk comes from the manufacturers

Wegovy self-pay through NovoCare starts at $149 per month for certain oral doses for new patients, with the standard pen from $199 per month for the first two months and the HD pen from $399 per month after introduction, all subject to change. Under the November 6, 2025 agreements, starting doses are offered at $350 per month via TrumpRx, trending toward $245 over two years, with roughly $150 per month for oral GLP-1s if approved.

If your program's value proposition rests on price on a molecule, the counterparty compressing that price is the company that makes it. This is a permanent competitive condition, not a phase.

Coverage risk cuts both ways

The Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027 at a $50 monthly copay. Large-employer coverage rose from 28% in 2024 to 43% in 2025. Both trends reduce the cash-pay population at the margin.

At the same time, 59% of the largest covering firms reported utilisation above projections and 66% reported significant prescription drug spending impact, which are the classic preconditions for employers restricting coverage again. And the BALANCE model was already delayed indefinitely for Medicare Part D after plan participation fell short of an 80% threshold.

The honest statement is that coverage is volatile in both directions and neither direction is safe to plan on.

The risks that attach to buying a build, including from us

There is no FDD. A license structure carries no mandated disclosure of litigation history, no audited financial statements, no mandated list of prior buyers to contact, and no substantiated performance representation. You must generate that protection yourself through the contract and the diligence on page fourteen. We would rather say that plainly than let the absence pass unmentioned.

Counterparty risk: if the seller ceases operating, what continues? Your entity, brand, member list, clinical relationship and supply relationships should all survive independently of the seller. If any of them do not, you have concentration risk you may not have priced.

Execution risk: a build removes assembly work. It does not remove operating work. Acquisition, staffing, compliance and retention remain yours, and no build quality compensates for an operator who is not present.

Category risk: this is a competitive, well-capitalised space with direct-to-consumer entrants who have advertising budgets you will not match. Differentiation has to be real, and local presence, clinical relationship and program depth are where it is available.

Concentration risk: a business built around one molecule class is exposed to that class's regulatory, supply and pricing conditions simultaneously. Breadth of program is a risk control, not just a value proposition.

What we cannot tell you

We cannot tell you what you will make. Not a range, not a scenario, not a labelled hypothetical. Atlas has no FDD, so there is no substantiated basis for any earnings figure, and publishing one anyway would be exactly the practice that page fourteen teaches you to treat as disqualifying.

We cannot guarantee supply, because a channel's regulatory basis is under active proposal. We cannot promise results, clinical or commercial. And we cannot advise you on the law in your state, which is why every regulatory passage in this blueprint is framed as something to verify with your own counsel.

If those absences make Atlas less attractive than a company that promises all four, that is a decision you are entitled to make with full information. We think the promises are the risk.

FREQUENTLY ASKED QUESTIONS.